DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
LDK378 is an investigational drug.
There have been 29 clinical trials for LDK378. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2015.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Lymphoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).
There are thirty-four US patents protecting this investigational drug and six hundred and seventy-nine international patents.
Recent Clinical Trials for LDK378
|Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-Small Cell Lung Cancer (The NCI-NRG ALK Master Protocol)||National Cancer Institute (NCI)||Phase 2|
|A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement||Yonsei University||Phase 2|
|Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma||National Cancer Institute (NCI)||Phase 1/Phase 2|
Top disease conditions for LDK378
Top clinical trial sponsors for LDK378
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|LDK378||Start Trial||Polycyclic inhibitor of anaplastic lymphoma kinase||XUANZHU PHARMA CO., LTD. (Jinan, Shandong Province, CN)||Start Trial|
|LDK378||Start Trial||Hydrate of 2-isopropoxy-5-methyl-4-(piperidin-4-yl) aniline dihydrochloride, preparation method and use of the same||2Y-CHEM, LTD. (Shanghai, CN)||Start Trial|
|LDK378||Start Trial||Inhibitors of ACK1/TNK2 tyrosine kinase||H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL)||Start Trial|
|LDK378||Start Trial||Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor||Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|LDK378||European Patent Office||3202765||2034-09-29||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|